VISTN Vistin Pharma ASA

Vistin Pharma ASA (VISTN): Update from the Election Committee

Vistin Pharma ASA (VISTN): Update from the Election Committee

Oslo, Norway, 07 May 2025

The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA.

The Election Committee has therefore assessed the consequences of this for the recommendation submitted 13 March 2025 to this year's annual general meeting. Øystein Spetalen was the only board member up for election, and it was recommended that he was re-elected. The composition of the board's expertise has been assessed, and it has been investigated whether other major shareholders who are not currently represented on the board may be relevant to the board. The Election Committee's conclusion is that Øystein Spetalen is not proposed to be replaced with a new board member and that the board is thereby reduced by one board member. Otherwise, the recommendation stands as it was submitted on 13 March 2025.

Item 9 from the call to the annual general meeting will therefore be withdrawn.





EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE

Vistin Pharma ASA: Mandatory notification of trade

Vistin Pharma ASA: Mandatory notification of trade Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.   Attachment

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Key information relating to the proposed ca...

Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend The Board of Directors will propose for the AGM to get a power of attorney to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November, for the accounting year of 2025. The formal decision regarding the dividend will be made on the company's Annual General Meeting, which will be held on 20 May 2026. Dividend amount (per share): NOK 1 Declared currency: NOK Last day including right: 21 May 2026 Ex-date: 22 May 2026 Record date: 26 May...

 PRESS RELEASE

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial resul...

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2025. Solid last quarter of 2025 signs-off a record year for Vistin Pharma with all-time high revenue and EBITDA. Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 114 in Q4 2024. Record high sales volume in quarter (+9%), offset by lower global metformin prices compared to same quarter last year. 2025 full year revenue ended at all-time high MNOK 452 com...

 PRESS RELEASE

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call

Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registrati...

 PRESS RELEASE

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch